Table 1

Baseline characteristics of patients

CharacteristicISDM-P group (n=151)Control group (n=128)
Women67 (44.4)59 (46.1)
Age, years59.5 (6.5)58.7 (7.9)
Duration of diabetes, years*8.5 (6.5)7.5 (6.2)
Systolic blood pressure, mm Hg†140 (15.1)140 (16.0)
Diastolic blood pressure, mm Hg†81 (8.9)84 (8.5)
Body mass index, kg/m233.6 (5.3)31.5 (6.7)
HbA1c, %§7.0 (0.7)7.0 (1.0)
Total cholesterol†, mmol/L5.2 (1.1)5.3 (1.1)
High-density lipoprotein , mmol/L1.3 (0.4)1.3 (0.4)
Low-density lipoprotein, mmol/L3.2 (0.9)3.4 (1.0)
Smoker (%)**29 (19.2)18 (14.5)
Diagnosis hypertension (%)†134 (88.7)115 (90.6)
Medication for blood pressure control (%)129 (85.4)104 (81.3)
Medication for glucose control124 (82.1)95 (74.2)
Insulin36 (23.8)28 (21.9)
Metformin111 (73.5)88 (68.8)
Sulfonylurea21 (13.9)10 (7.8)
Other antidiabetic agents52 (34.4)40 (31.3)
Statin medication50 (33.1)41 (32.0)
Participation in teaching session for hypertension†† (%)28 (21.1)11 (10.1)
Graduation
 None1 (0.7)1 (0.8)
 Junior high school29 (19.2)24 (18.8)
 High school93 (61.6)86 (67.2)
 Qualification for technical college or university28 (18.5)17 (13.3)
  • Values are given as patient number (percentage) or as means (SD).

  • *ISDM-P n=151, control group n=125.

  • †ISDM-P n=151, control group n=127.

  • ‡ISDM-P n=150, control group n=126.

  • §ISDM-P n=151, control group n=128.

  • ¶ISDM-P n=150, control group n=117.

  • **ISDM-P n=151, control group n=124.

  • ††Patients with diagnosis of hypertension, ISDM-P n=133, control group n=109.

  • HbA1c, glycated haemoglobin; ISDM-P, informed shared decision-making programme.